ANIP
vs
S&P 500
Over the past 12 months, ANIP has underperformed S&P 500, delivering a return of -4% compared to the S&P 500's 24% growth.
Stocks Performance
ANIP vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
|
US |
Eli Lilly and Co
NYSE:LLY
|
||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
||
US |
Johnson & Johnson
NYSE:JNJ
|
||
US |
Merck & Co Inc
NYSE:MRK
|
||
CH |
Roche Holding AG
SIX:ROG
|
||
UK |
AstraZeneca PLC
LSE:AZN
|
||
CH |
Novartis AG
SIX:NOVN
|
||
US |
Pfizer Inc
NYSE:PFE
|
Performance Gap
ANIP vs S&P 500
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
|
US |
Eli Lilly and Co
NYSE:LLY
|
||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
||
US |
Johnson & Johnson
NYSE:JNJ
|
||
US |
Merck & Co Inc
NYSE:MRK
|
||
CH |
Roche Holding AG
SIX:ROG
|
||
UK |
AstraZeneca PLC
LSE:AZN
|
||
CH |
Novartis AG
SIX:NOVN
|
||
US |
Pfizer Inc
NYSE:PFE
|
Performance By Year
ANIP vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
|
US |
Eli Lilly and Co
NYSE:LLY
|
||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
||
US |
Johnson & Johnson
NYSE:JNJ
|
||
US |
Merck & Co Inc
NYSE:MRK
|
||
CH |
Roche Holding AG
SIX:ROG
|
||
UK |
AstraZeneca PLC
LSE:AZN
|
||
CH |
Novartis AG
SIX:NOVN
|
||
US |
Pfizer Inc
NYSE:PFE
|
Competitors Performance
ANI Pharmaceuticals Inc vs Peers
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
US |
G
|
GE Vernova LLC
NYSE:GEV
|
|
NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
|
US |
Schlumberger NV
NYSE:SLB
|
||
US |
B
|
Baker Hughes Co
NASDAQ:BKR
|
|
ID |
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
||
US |
R
|
Reddit Inc
NYSE:RDDT
|
|
CH |
G
|
Galderma Group AG
SIX:GALD
|
|
US |
Halliburton Co
NYSE:HAL
|
||
IN |
Jio Financial Services Ltd
NSE:JIOFIN
|
||
LU |
Tenaris SA
MIL:TEN
|
ANI Pharmaceuticals Inc
Glance View
ANI Pharmaceuticals Inc. operates at the heart of the pharmaceutical industry with a focused strategy that blends generics with niche high-value medications. Born in the realm of specialty pharmaceuticals, the company has crafted a business model that leverages both organic growth and strategic acquisitions. This dual approach helps the company to broaden its product offerings and maintain a robust pipeline. By targeting niche markets often overlooked by larger pharmaceutical giants, ANI maximizes its opportunities in areas with less competitive congestion. Central to its operations is the manufacturing and marketing of generic prescription products that are not only critically required but also pose less risk of commoditization due to their complexity, regulatory hurdles, or limited manufacturing capabilities. Revenue generation for ANI is a sophisticated blend of manufacturing, marketing, and brand positioning. The company's infrastructure supports integrated product development, regulatory approval, and scalable manufacturing processes. This allows them to efficiently bring to market a diverse portfolio of more than a hundred products across therapeutic areas. Additionally, ANI taps into revenue streams by producing legacy branded drugs often acquired from larger players looking to offload non-core assets. These legacy products, while sometimes in smaller volumes, benefit from loyal prescriber bases and established market presence, providing a steady income for the company. In essence, ANI Pharmaceuticals thrives on navigating the intricacies of the pharmaceutical supply chain, seizing opportunities in underexplored niches and refocusing the potential of undervalued brands.